Last updated: April 29, 2026
What is OMNIPAQUE 210 and how is it positioned in the market?
OMNIPAQUE 210 is a brand of iohexol (non-ionic, low-osmolality iodinated contrast media) formulated at 210 mg iodine/mL and used for computed tomography (CT) and related radiology. In routine markets, its core demand driver is diagnostic imaging volume rather than breakthrough clinical differentiation. Product performance depends on formulary access, supply reliability, pricing, and contracting across hospital systems, imaging centers, and national health programs.
Key product identifiers (commercial positioning)
- Active ingredient: Iohexol
- Strength: 210 mg iodine/mL (OMNIPAQUE 210)
- Class: Non-ionic iodinated contrast media
- Primary use setting: Radiology departments performing CT and other contrast-enhanced imaging
What does the clinical-trials pipeline show for OMNIPAQUE 210 specifically?
A drug- and dose-specific clinical-trials map for OMNIPAQUE 210 is not available in the public clinical-trials record with enough granularity to separate “OMNIPAQUE 210” from other iohexol strengths and related iodinated contrast pathways. The clinical literature and trial registries predominantly track iohexol (or broader iodinated contrast comparisons) rather than a single named strength line.
What is investable from a clinical-evidence standpoint is not dose-line differentiation, but ongoing evidence-generation and protocol-level comparisons around:
- Comparative tolerability and image quality across contrast media
- Dosing strategies (volume and rate) for CT workflows
- Use in high-risk subgroups (contrast-associated acute kidney injury, allergies, and severity stratification)
- Workflow optimization (injection protocols, delayed imaging, and imaging reconstruction methods)
Because the record does not cleanly isolate OMNIPAQUE 210-specific endpoints, the clinical update must be treated as class and active-ingredient level rather than proof of a new OMNIPAQUE 210 signal.
How does OMNIPAQUE 210 compete in the iodinated contrast market?
The competitive set is defined by non-ionic iodinated contrast agents and by switchability at formulary level. OMNIPAQUE (iohexol) competes most directly with other non-ionic low-osmolality iodinated agents, including (by typical market categories) iopamidol, iomeprol, ioversol, and iopromide, plus lower-cost generics where allowed.
Competitive vectors
- Formulary position and tender pricing (dominant in hospital contracting)
- Supply continuity (critical for imaging schedules)
- Volume-based purchasing for CT throughput
- Per-patient cost driven by vial sizes, dosing, and institutional protocols
- Clinical protocol lock-in where radiology groups standardize on injection systems and concentrations
Practical implication for OMNIPAQUE 210
OMNIPAQUE 210’s market outcomes track iohexol overall purchasing and 210 mg iodine/mL concentration selection within imaging protocols, not a unique mechanism of action.
What is the market size and demand driver profile?
The iodinated contrast media market is driven by:
- Rising CT utilization
- Aging populations and increased imaging frequency
- Expansion of outpatient imaging
- Lower barriers to imaging access in many health systems
This segment is mature and tends to show:
- Stable demand with periodic procurement-driven price compression
- Incremental shifts from brand to contract-preferred and generic-available products, where applicable
- Geographic variability based on reimbursement and tender rules
Market demand mechanics (how to model)
For projection modeling, iodinated contrast demand is typically driven by:
- CT scan volumes (or total contrast-enhanced imaging cases)
- Contrast usage per scan (mL per exam, and mix of strengths)
- Concentration mix (e.g., 300 vs 240 vs 210 in protocol selection)
- Switch rate among agents via formularies and purchasing contracts
- Price realization after tender and rebates
What are plausible market projections for OMNIPAQUE 210 over the next 5 years?
A strength-specific projection requires dose-mix and contract-mix assumptions that are not available in the public record at OMNIPAQUE 210 granularity. The only defensible projection approach from the available evidence is to tie OMNIPAQUE 210 to:
- Overall iohexol share and purchasing stability
- Contract dynamics in iodinated contrast tenders
- CT growth and protocol mix stability
Projection framework (scenario ranges)
Use three scenario bands for OMNIPAQUE 210 unit volume and price realization, then convert to revenue:
| Driver |
Base case |
Upside |
Downside |
| CT growth and imaging volume |
Moderate expansion |
Faster imaging growth |
Slower growth |
| Strength mix (210 share) |
Stable to slight normalization |
Slight increase from protocol preference |
Decrease from substitution to other concentrations |
| Competitive pricing / tender pressure |
Limited compression |
Intensified pressure limits net pricing |
Steeper price erosion via switches |
| Share retention (iohexol brand vs alternatives) |
Stable |
Better contract stickiness |
Contract losses increase substitution |
Resulting revenue pattern expected for 210 mg/mL products in a mature class:
- Flat-to-low single digit CAGR in revenue is most common for brand-anchored iodinated contrast lines under tender pressure.
- Upside tends to come from contract wins and improved share retention rather than new clinical evidence.
- Downside tends to come from displacement by lower-priced alternatives or concentration shifts within CT protocols.
What would change the trajectory materially?
- National tender outcomes where hospitals consolidate around fewer vendors
- Entry of lower-cost equivalents or stronger generic substitution in particular geographies
- Changes in imaging protocols that change average required mL and preferred concentration
What does the evidence base say about safety and effectiveness drivers?
In the absence of a 210-mg-only clinical-trial signal, safety and effectiveness drivers are framed by broad iohexol and iodinated contrast experience:
- Non-ionic low-osmolality contrast generally has favorable tolerability versus older high-osmolality agents
- Risk management focuses on renal impairment and prior contrast reactions
- Protocol adjustments (hydration, dosing, injection rates) influence real-world outcomes
This is consistent with how iodinated contrast procurement and protocol governance operate: radiology and hospital safety committees focus on the agent class, not only concentration strength.
How should businesses interpret OMNIPAQUE 210’s development outlook?
For a mature marketed iodinated contrast agent, “clinical development” usually means:
- Label maintenance and regulatory updates
- Risk communication and protocol refinements
- Evidence generation to support positioning in high-use pathways
The competitive edge stays operational:
- Contracting and distribution reliability
- Pricing under tender constraints
- Institutional standardization and radiology workflow fit
What is the actionable market strategy lens for OMNIPAQUE 210?
Contract and pricing levers
- Secure multi-site imaging network tenders to stabilize unit volume
- Defend per-scan cost positions using vial availability and dosing compatibility
- Negotiate around supply continuity and turnaround times during procurement cycles
Portfolio and protocol levers
- Position OMNIPAQUE 210 within concentration-mix protocols where it matches desired density and workflow injection rates
- Bundle training or protocol guidance with radiology group adoption plans
- Track concentration usage trends within CT to align marketing and supply planning
Competitive displacement defense
- Monitor conversion away from iohexol to other agents through formulary minutes and tender outcomes
- Target accounts where safety committees historically favor low-osmolality non-ionic agents
- Focus on hospital imaging volumes with stable annual scan counts
Key Takeaways
- OMNIPAQUE 210 is iohexol 210 mg iodine/mL, a mature non-ionic iodinated contrast product whose market performance is driven primarily by CT demand, tender contracting, and strength mix, not new clinical differentiation.
- A dose-specific clinical-trials update for OMNIPAQUE 210 is not cleanly separable in public registries; the usable clinical view is class and iohexol-level evidence generation and safety governance.
- Projections for the next five years should be built on CT volume growth plus tender-driven pricing and share retention; the most likely revenue outcome for a strength-specific, brand-anchored contrast line is flat-to-low single digit growth with meaningful downside risk from substitution and tender pressure.
- The most actionable levers are contract wins, pricing discipline, supply continuity, and alignment with CT concentration protocols.
FAQs
-
Is there new OMNIPAQUE 210 efficacy evidence changing its clinical standing?
Public clinical activity is not dose-specific enough to indicate a standalone OMNIPAQUE 210 breakthrough; evidence remains anchored in class and iohexol experience.
-
What determines OMNIPAQUE 210 demand most?
CT utilization volume, contrast per-exam dosing norms, and institutional concentration selection in CT protocols.
-
How do hospitals typically choose OMNIPAQUE 210?
Through formulary/tender contracting, safety committee governance, and total per-scan cost rather than mechanism-based differentiation.
-
What is the biggest risk to OMNIPAQUE 210 revenue?
Tender-driven substitution to lower-cost non-ionic iodinated alternatives and shifts in protocol concentration mix.
-
What is the best commercial path for growth in OMNIPAQUE 210?
Multi-site contract retention with stable pricing and supply continuity, paired with protocol fit for the 210 mg/mL concentration workflow.
References
[1] U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
[2] European Medicines Agency. Public assessment reports and product information for iodinated contrast media (iohexol). https://www.ema.europa.eu/
[3] American College of Radiology (ACR). Manual on Contrast Media (general iodinated contrast guidance). https://www.acr.org/Clinical-Resources/Contrast-Manual
